Inhibitor of Growth-4 Mediates Chromatin Modification and Has a Suppressive Effect on Tumorigenesis and Innate Immunity

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2011 Oct 6

PMID 21971889

Citations 8

Authors

Vivek Bhakta Mathema

Young-Sang Koh

Affiliations

Soon will be listed here.

Abstract

Inhibitor of growth-4 (ING4) is a member of the ING family and acts as a tumor suppressor protein. ING4 is a promising candidate for cancer research due to its anti-angiogenic function and its role in the inhibition of cell migration, cell cycle, and induction of apoptosis. Interaction of this protein with the histone acetyl transferase complex plays a vital role in the regulation of multiple nuclear factor kappa light chain enhancer of activated B cells response elements and thus in the regulation of innate immunity. Splice variants of ING4 have different binding affinities to target sites, which results in the enhancement of its functional diversity. ING4 is among the few known regulatory proteins that can directly interact with chromatin as well as with transcription factors. The influence of ING4 on tumor necrosis factor-α, keratinocyte chemoattractant, interleukin (IL)-6, IL-8, matrix metalloproteinases, cyclooxygenase-2, and IκBα expression clearly demonstrates its critical role in the regulation of inflammatory mediators. Its interaction with liprin α1 and p53 contribute to mitigate cell spreading and induce apoptosis of cancer cells. Multiple factors including breast cancer melanoma suppressor-1 are upstream regulators of ING4 and are frequently deactivated in tumor cells. In the present review, the different properties of ING4 are discussed, and its activities are correlated with different aspects of cell physiology. Special emphasis is placed on our current understanding of ING4 with respect to its influence on chromatin modification, tumorigenesis, and innate immunity.

Citing Articles

Ing4-deficiency promotes a quiescent yet transcriptionally poised state in hematopoietic stem cells.

Thompson Z, Anderson G, Hernandez M, Quinde C, Marchione A, Rodriguez M iScience. 2024; 27(8):110521.

PMID: 39175773 PMC: 11340613. DOI: 10.1016/j.isci.2024.110521.

Esx Factors Control Human Dendritic Cell Functions Conditioning Th1/Th17 Response.

Cruciani M, Etna M, Camilli R, Giacomini E, Percario Z, Severa M Front Cell Infect Microbiol. 2017; 7:330.

PMID: 28785545 PMC: 5519619. DOI: 10.3389/fcimb.2017.00330.

Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Yang J, Ge H, Poulton C, Hogan S, Hu Y, Jones B Clin Epigenetics. 2016; 8:85.

PMID: 27752292 PMC: 5057507. DOI: 10.1186/s13148-016-0251-0.

Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma.

Zhao D, Liu X, Zhang Y, Ding Z, Dong F, Xu H Oncol Lett. 2016; 11(4):2869-2874.

PMID: 27073567 PMC: 4812461. DOI: 10.3892/ol.2016.4324.

Inhibitor of growth-4 is a potential target for cancer therapy.

Yuan S, Jin J, Shi J, Hou Y Tumour Biol. 2016; 37(4):4275-9.

PMID: 26803518 DOI: 10.1007/s13277-016-4842-3.

References

Nozell S, Laver T, Moseley D, Nowoslawski L, De Vos M, Atkinson G . The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol. 2008; 28(21):6632-45. PMC: 2573235. DOI: 10.1128/MCB.00697-08. View

Ahn K, Sethi G, Aggarwal B . Nuclear factor-kappa B: from clone to clinic. Curr Mol Med. 2007; 7(7):619-37. DOI: 10.2174/156652407782564363. View

Rothe M, Sarma V, Dixit V, Goeddel D . TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 1995; 269(5229):1424-7. DOI: 10.1126/science.7544915. View

Serra-Pages C, Kedersha N, Fazikas L, Medley Q, Debant A, Streuli M . The LAR transmembrane protein tyrosine phosphatase and a coiled-coil LAR-interacting protein co-localize at focal adhesions. EMBO J. 1995; 14(12):2827-38. PMC: 398401. DOI: 10.1002/j.1460-2075.1995.tb07282.x. View

Li X, Kikuchi K, Takano Y . ING Genes Work as Tumor Suppressor Genes in the Carcinogenesis of Head and Neck Squamous Cell Carcinoma. J Oncol. 2010; 2011:963614. PMC: 2968421. DOI: 10.1155/2011/963614. View

Palacios A, Moreno A, Oliveira B, Rivera T, Prieto J, Garcia P . The dimeric structure and the bivalent recognition of H3K4me3 by the tumor suppressor ING4 suggests a mechanism for enhanced targeting of the HBO1 complex to chromatin. J Mol Biol. 2010; 396(4):1117-27. DOI: 10.1016/j.jmb.2009.12.049. View

Zhang X, Wang K, Wang Z, Xu L, Wang Q, Chen F . Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun. 2005; 331(4):1032-8. DOI: 10.1016/j.bbrc.2005.04.023. View

Moreno A, Palacios A, Orgaz J, Jimenez B, Blanco F, Palmero I . Functional impact of cancer-associated mutations in the tumor suppressor protein ING4. Carcinogenesis. 2010; 31(11):1932-8. DOI: 10.1093/carcin/bgq171. View

Li J, Martinka M, Li G . Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis. 2008; 29(7):1373-9. DOI: 10.1093/carcin/bgn086. View

10.

Shen J, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K . Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res. 2007; 67(6):2552-8. PMC: 2569966. DOI: 10.1158/0008-5472.CAN-06-3870. View

11.

Saha A, Bamidele A, Murakami M, Robertson E . EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol. 2010; 85(5):2079-88. PMC: 3067769. DOI: 10.1128/JVI.02279-10. View

12.

Hurst D, Edmonds M, Welch D . Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009; 69(19):7495-8. PMC: 2756311. DOI: 10.1158/0008-5472.CAN-09-2111. View

13.

Coles A, Gannon H, Cerny A, Kurt-Jones E, Jones S . Inhibitor of growth-4 promotes IkappaB promoter activation to suppress NF-kappaB signaling and innate immunity. Proc Natl Acad Sci U S A. 2010; 107(25):11423-8. PMC: 2895088. DOI: 10.1073/pnas.0912116107. View

14.

Lei X, Bai Z, Ye F, Xie J, Kim C, Huang Y . Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat Cell Biol. 2010; 12(2):193-9. PMC: 2815189. DOI: 10.1038/ncb2019. View

15.

Cai L, Li X, Zheng S, Wang Y, Wang Y, Li H . Inhibitor of growth 4 is involved in melanomagenesis and induces growth suppression and apoptosis in melanoma cell line M14. Melanoma Res. 2009; 19(1):1-7. DOI: 10.1097/CMR.0b013e32831bc42f. View

16.

Raho G, Miranda C, Tamborini E, Pierotti M, Greco A . Detection of novel mRNA splice variants of human ING4 tumor suppressor gene. Oncogene. 2007; 26(36):5247-57. DOI: 10.1038/sj.onc.1210335. View

17.

Krusche C, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L . Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005; 90(1):15-23. DOI: 10.1007/s10549-004-1668-2. View

18.

Palacios A, Munoz I, Pantoja-Uceda D, Marcaida M, Torres D, Martin-Garcia J . Molecular basis of histone H3K4me3 recognition by ING4. J Biol Chem. 2008; 283(23):15956-64. PMC: 3259640. DOI: 10.1074/jbc.M710020200. View

19.

Takeuchi O, Akira S . Pattern recognition receptors and inflammation. Cell. 2010; 140(6):805-20. DOI: 10.1016/j.cell.2010.01.022. View

20.

Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, Haraguchi M . Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer. 2004; 110(3):362-7. DOI: 10.1002/ijc.20154. View